Biomarker & Intervention Discovery

Type 2 Diabetes

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

US DALYs5.06MWHO GHE 2021 · all ages
Global DALYs80.11MWHO GHE 2021 · worldwide
US mortality61.1K deaths/yrWHO GHE 2021
Global mortality1.61M deaths/yrWHO GHE 2021 · worldwide
NIH funding$1.10BFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remission1.6-1.7% at 7 years on standard care (population-level cohorts UK and US)
Best-intervention remission46-58% at 5 years post-bariatric surgery; up to 86% at 1 year with >15% total weight loss via intensive dietary…
Gap sizeVery large
Primary barrierpractice/access
Full remission profile →

Remission & chronicity

Spontaneous remission
1.6-1.7% at 7 years on standard care (population-level cohorts UK and US)
Best-intervention remission
46-58% at 5 years post-bariatric surgery; up to 86% at 1 year with >15% total weight loss via intensive dietary intervention (DiRECT trial: 36% at 2 years)
Gap size
Very large
Primary barrier
practice/access
Remission is biologically achievable and demonstrated in multiple large RCTs but almost never offered as the primary clinical strategy; default is indefinite pharmacotherapy escalation
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ADIPOQ 4DPP4 234FOXO1 26GCGR 184GLP1R 166INSR 78IRS1 16LEPR 6PPARG 127PRKAA1 202SLC2A4 65SLC5A2 190
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NEVIRAPINE ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SPIRONOLACTONE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TCDD ? unclear Mechanistic
LINAGLIPTIN inhibits Mechanistic
GOSOGLIPTIN inhibits Mechanistic
BEGELOMAB inhibits Mechanistic
VALACYCLOVIR ? unclear Mechanistic
GEMIGLIPTIN inhibits Mechanistic
ENMD-2076 inhibits Mechanistic
SITRAVATINIB inhibits Mechanistic
CRENOLANIB inhibits Mechanistic
CP-673451 inhibits Mechanistic
NINTEDANIB ESYLATE inhibits Mechanistic
IBCASERTIB inhibits Mechanistic
LUCITANIB inhibits Mechanistic
SAXAGLIPTIN ANHYDROUS ? unclear Mechanistic
DBPR-108 inhibits Mechanistic
M4205 inhibits Mechanistic
COMPOUND 8H [PMID: 22765894] inhibits Mechanistic
DOVITINIB inhibits Mechanistic
MELOGLIPTIN ? unclear Mechanistic
PP-121 inhibits Mechanistic
EVOGLIPTIN inhibits Mechanistic
ILORASERTIB inhibits Mechanistic
AC710 inhibits Mechanistic
MASITINIB inhibits Mechanistic
ALOGLIPTIN BENZOATE inhibits Mechanistic
QUIZARTINIB inhibits Mechanistic
CHMFL-KIT-64 inhibits Mechanistic
VILDAGLIPTIN inhibits Mechanistic 34.0 nM (IC50)
SERALUTINIB inhibits Mechanistic
CAPTOPRIL ? unclear Mechanistic
TRELAGLIPTIN SUCCINATE inhibits Mechanistic
ENALAPRIL MALEATE ? unclear Mechanistic
COMPOUND 8H [PMID: 21561767] inhibits Mechanistic
TENELIGLIPTIN inhibits Mechanistic
ELENESTINIB inhibits Mechanistic
CARMEGLIPTIN inhibits Mechanistic
ANAGLIPTIN inhibits Mechanistic
SITAGLIPTIN inhibits Mechanistic
DUTOGLIPTIN inhibits Mechanistic
BISEGLIPTIN ? unclear Mechanistic

Showing top 40 of 234 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FAS LIGAND ? unclear Mechanistic
FLUOROURACIL ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
EPIRUBICIN ? unclear Mechanistic
PSAMMAPLYSENE A inhibits Mechanistic 5000.0 nM (IC50)
PSAMMAPLYSENE B inhibits Mechanistic 20000.0 nM (IC50)
CHEMBL5192734 inhibits Mechanistic 33.0 nM (IC50)
CHEMBL5410786 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5427016 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5430492 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5438402 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5422565 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5401913 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5416762 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5432660 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5440152 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5435132 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5435547 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5433566 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5424486 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5423837 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5410704 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5405275 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5440878 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL5413713 inhibits Mechanistic 1000.0 nM (IC50)
PANOBINOSTAT activates Mechanistic 420.0 nM (EC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
REDIOCIDE A ? unclear Mechanistic
ADOMEGLIVANT inhibits Mechanistic
GLUCAGON (RDNA) activates Mechanistic
CROTEDUMAB inhibits Mechanistic
PEMETREXED DISODIUM inhibits Mechanistic
LGD-6972 ? unclear Mechanistic
COTADUTIDE activates Mechanistic
GLUCAGON HYDROCHLORIDE activates Mechanistic
MK-0893 inhibits Mechanistic
PEGAPAMODUTIDE ? unclear Mechanistic
PF-06291874 inhibits Mechanistic
EFINOPEGDUTIDE activates Mechanistic
CAPECITABINE inhibits Mechanistic
RALTITREXED inhibits Mechanistic
DASIGLUCAGON HYDROCHLORIDE activates Mechanistic
DASIGLUCAGON activates Mechanistic
MK-3577 inhibits Mechanistic
VOLAGIDEMAB inhibits Mechanistic
SAR425899 activates Mechanistic
GLUCAGON ? unclear Mechanistic
CHEMBL140267 inhibits Mechanistic 7500.0 nM (IC50)
CHEMBL346451 inhibits Mechanistic 20000.0 nM (Ki)
CHEMBL358250 inhibits Mechanistic 120.0 nM (IC50)
CHEMBL140209 inhibits Mechanistic 6000.0 nM (IC50)
CHEMBL142414 inhibits Mechanistic 220.0 nM (IC50)
CHEMBL142944 inhibits Mechanistic 250.0 nM (IC50)
CHEMBL25637 inhibits Mechanistic 110.0 nM (IC50)
CHEMBL356726 inhibits Mechanistic 9200.0 nM (Ki)
CHEMBL356089 inhibits Mechanistic 150.0 nM (IC50)
CHEMBL422833 inhibits Mechanistic 240.0 nM (IC50)
CHEMBL146839 inhibits Mechanistic 20000.0 nM (Ki)
CHEMBL140514 inhibits Mechanistic 400.0 nM (IC50)
CHEMBL140268 inhibits Mechanistic 700.0 nM (IC50)
CHEMBL436011 inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL140317 inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL140586 inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL358546 inhibits Mechanistic 55000.0 nM (Ki)
CHEMBL140636 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL148905 inhibits Mechanistic 73000.0 nM (Ki)
CHEMBL344911 inhibits Mechanistic 1800.0 nM (IC50)

Showing top 40 of 184 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL:CHEMBL607309 ? unclear Mechanistic
CHEMBL:CHEMBL585444 ? unclear Mechanistic
CHEMBL:CHEMBL1327172 ? unclear Mechanistic
CHEMBL:CHEMBL1224483 ? unclear Mechanistic
CGP13501 ? unclear Mechanistic
CHEMBL:CHEMBL580340 ? unclear Mechanistic
EFPEGLENATIDE activates Mechanistic
LIRAGLUTIDE ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL597251 ? unclear Mechanistic
ANGUSTIBALIN ? unclear Mechanistic
DULAGLUTIDE activates Mechanistic
EXENATIDE activates Mechanistic
MOFEBUTAZONE ? unclear Mechanistic
CHEMBL:CHEMBL532412 ? unclear Mechanistic
NORTRIPTYLINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL533602 ? unclear Mechanistic
PEGSEBRENATIDE activates Mechanistic
OLANZAPINE ? unclear Mechanistic
CHEMBL:CHEMBL317115 ? unclear Mechanistic
CHEMBL:CHEMBL1549738 ? unclear Mechanistic
CYCLOASPEPTIDE A ? unclear Mechanistic
SCOULERINE ? unclear Mechanistic
KEPONE ? unclear Mechanistic
PEGAPAMODUTIDE activates Mechanistic
CHEMBL:CHEMBL603154 ? unclear Mechanistic
ETOPOSIDE ? unclear Mechanistic
CHEMBL:CHEMBL405914 ? unclear Mechanistic
CHEMBL:CHEMBL1308346 ? unclear Mechanistic
FIDUXOSIN HYDROCHLORIDE ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
CHEMBL:CHEMBL578515 ? unclear Mechanistic
CHEMBL:CHEMBL1439833 ? unclear Mechanistic
CHEMBL:CHEMBL601351 ? unclear Mechanistic
CHEMBL:CHEMBL580727 ? unclear Mechanistic
AMORFRUTIN A ? unclear Mechanistic
PROPIONYLPROMAZINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL588038 ? unclear Mechanistic
CHEMBL:CHEMBL1420370 ? unclear Mechanistic
CHEMBL:CHEMBL580207 ? unclear Mechanistic

Showing top 40 of 166 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TESOFENSINE ? unclear Mechanistic
INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN activates Mechanistic
GO-6976 ? unclear Mechanistic
INSULIN ZINC, PROMPT activates Mechanistic
INSULIN PURIFIED PORK activates Mechanistic
INSULIN ZINC SUSP EXTENDED PURIFIED BEEF activates Mechanistic
INSULIN ZINC, EXTENDED activates Mechanistic
INSULIN ZINC SUSP EXTENDED BEEF activates Mechanistic
INSULIN ZINC SUSP BEEF activates Mechanistic
INSULIN SENSITIZER S-707106 ? unclear Mechanistic
SP-600125 ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
INSULIN DETEMIR activates Mechanistic
INSULIN DEGLUDEC activates Mechanistic
AEW-541 ? unclear Mechanistic
ILORASERTIB ? unclear Mechanistic
NVP-TAE684 ? unclear Mechanistic
INSULIN ASPART PROTAMINE RECOMBINANT activates Mechanistic
INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF activates Mechanistic
INSULIN, PROTAMINE ZINC activates Mechanistic
INSULIN TREGOPIL activates Mechanistic
INSULIN, REGULAR, HUMAN activates Mechanistic
PF-562271 ? unclear Mechanistic
INSULIN SUSP PROTAMINE ZINC PURIFIED PORK activates Mechanistic
RECOMBINANT HUMAN KALLIKREIN-1 ? unclear Mechanistic
LINIFANIB ? unclear Mechanistic
INSULIN [INJECTION], BIPHASIC activates Mechanistic
INSULIN HUMAN, ISOPHANE activates Mechanistic
INSULIN SUSP ISOPHANE PURIFIED PORK activates Mechanistic
INSULIN ZINC SUSP PURIFIED PORK activates Mechanistic
RG-1530 ? unclear Mechanistic
EPIRUBICIN ? unclear Mechanistic
INSULIN ASPART PROTAMINE, HUMAN activates Mechanistic
TOZASERTIB ? unclear Mechanistic
TOPIRAMATE ? unclear Mechanistic
LINSITINIB inhibits Mechanistic
INSULIN LISPRO activates Mechanistic
INSULIN LISPRO PROTAMINE RECOMBINANT activates Mechanistic
INSULIN SUSP ISOPHANE BEEF/PORK activates Mechanistic
MITOGLITAZONE ? unclear Mechanistic

Showing top 40 of 78 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AGANIRSEN ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
FLUOROURACIL ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
PRASTERONE ? unclear Mechanistic
EPIRUBICIN ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
CHEMBL1685056 inhibits Mechanistic 50.0 nM (Kd)
CHEMBL1685055 inhibits Mechanistic 150.0 nM (Kd)
CHEMBL1681823 inhibits Mechanistic 50.0 nM (Kd)
CHEMBL4536878 inhibits Mechanistic 120.0 nM (Kd)
CHEMBL4591779 inhibits Mechanistic 16200.0 nM (Kd)
CHEMBL4530453 inhibits Mechanistic 1600.0 nM (Kd)
CHEMBL1572640 inhibits Mechanistic 3300.0 nM (Kd)
CHEMBL4576057 inhibits Mechanistic 16400.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MIBAVADEMAB activates Mechanistic
SIMVASTATIN ? unclear Mechanistic
VALPROIC ACID ? unclear Mechanistic
METRELEPTIN activates Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
SETMELANOTIDE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
METHOXYCHLOR ? unclear Mechanistic
CHEMBL:CHEMBL2208197 ? unclear Mechanistic
PROPYLPYRAZOLETRIOL ? unclear Mechanistic
LANIFIBRANOR activates Mechanistic
PROPYLPARABEN ? unclear Mechanistic
ABIETIC ACID ? unclear Mechanistic
KEPONE ? unclear Mechanistic
SPIRONOLACTONE ? unclear Mechanistic
FLUOXASTROBIN ? unclear Mechanistic
ROSIGLITAZONE MALEATE activates Mechanistic
CHEMBL:CHEMBL2178583 ? unclear Mechanistic
NAVEGLITAZAR activates Mechanistic
CELECOXIB ? unclear Mechanistic
SHINPTEROCARPIN ? unclear Mechanistic
PSAMMAPLIN A ? unclear Mechanistic
TECNAZENE ? unclear Mechanistic
MYCOPHENOLATE ? unclear Mechanistic
CHEMBL:CHEMBL1833984 ? unclear Mechanistic
IMIGLITAZAR activates Mechanistic
ROSIGLITAZONE ? unclear Mechanistic
CLX-0921 activates Mechanistic
AVE0847 activates Mechanistic
CHLORFENAPYR ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE activates Mechanistic
PROCHLORAZ ? unclear Mechanistic
MESALAMINE activates Mechanistic
BEZAFIBRATE activates Mechanistic
CHEMBL:CHEMBL312032 ? unclear Mechanistic
ISOSILYBIN A ? unclear Mechanistic
AMORFRUTIN A ? unclear Mechanistic
NALED ? unclear Mechanistic
TROGLITAZONE activates Mechanistic
PROSTAGLANDIN D2 ? unclear Mechanistic
INT131 ~ modulates Mechanistic
EFATUTAZONE HYDROCHLORIDE activates Mechanistic
FLUORODIFEN ? unclear Mechanistic
FLUDIOXONIL ? unclear Mechanistic
ESTRADIOL VALERATE ? unclear Mechanistic
CHEMBL:CHEMBL166112 ? unclear Mechanistic
BENSULIDE ? unclear Mechanistic

Showing top 40 of 127 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
GW441756X ? unclear Mechanistic
PD-0166285 ? unclear Mechanistic 316.23 nM (Ki)
CENISERTIB ? unclear Mechanistic
CYC-116 ? unclear Mechanistic 501.19 nM (Ki)
PENTOSTATIN ? unclear Mechanistic
PALBOCICLIB ? unclear Mechanistic
JNJ-7706621 ? unclear Mechanistic 1700.0 nM (Kd)
PF-562271 ? unclear Mechanistic
TOZASERTIB ? unclear Mechanistic 1100.0 nM (Kd)
STREPTOZOCIN ? unclear Mechanistic
DOVITINIB ? unclear Mechanistic 520.0 nM (Kd)
TYROSINE KINASE INHIBITOR ? unclear Mechanistic
METFORMIN ? unclear Mechanistic
RG-1530 ? unclear Mechanistic
LY-2090314 ? unclear Mechanistic 630.96 nM (Ki)
ADENOSINE DEAMINASE INHIBITOR ? unclear Mechanistic
SAPONARIN ? unclear Mechanistic
CHEMBL:CHEMBL587615 ? unclear Mechanistic
CHEMBL:CHEMBL1997335 ? unclear Mechanistic
ENTRECTINIB ? unclear Mechanistic 251.19 nM (Ki)
SIROLIMUS ? unclear Mechanistic
ILORASERTIB ? unclear Mechanistic
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic
CHEMBL:CHEMBL379975 ? unclear Mechanistic
HESPERADIN inhibits Mechanistic 19.0 nM (Kd)
PHENFORMIN ? unclear Mechanistic
THYROXINE ? unclear Mechanistic
ACADESINE activates Mechanistic
CHEMOPREVENTIVE AGENT ? unclear Mechanistic
SOTRASTAURIN ? unclear Mechanistic 630.96 nM (Ki)
NVP-TAE684 ? unclear Mechanistic
METFORMIN HYDROCHLORIDE activates Mechanistic
SUNITINIB inhibits Mechanistic 52.0 nM (Kd)
ALVOCIDIB inhibits Mechanistic 6600.0 nM (Kd)
STAUROSPORINE inhibits Mechanistic 9.0 nM (Kd)
VANDETANIB inhibits Mechanistic 10000.0 nM (Kd)
AST-487 inhibits Mechanistic 1400.0 nM (Kd)
RAF-265 inhibits Mechanistic 4500.0 nM (Kd)
MIDOSTAURIN inhibits Mechanistic 180.0 nM (Kd)
SU-014813 inhibits Mechanistic 100.0 nM (Kd)

Showing top 40 of 202 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
PROTEASE INHIBITOR ? unclear Mechanistic
CLOFIBRATE ? unclear Mechanistic
ESTRADIOL 3-BENZOATE ? unclear Mechanistic
GLUFOSFAMIDE ? unclear Mechanistic
CALCIUM CHANNEL BLOCKER ? unclear Mechanistic
BUTHIONINE SULFOXIMINE ? unclear Mechanistic
THEAFLAVIN ? unclear Mechanistic
TROGLITAZONE ? unclear Mechanistic
TCDD ? unclear Mechanistic
STAUROSPORINE ? unclear Mechanistic
GENISTEIN ? unclear Mechanistic
HEPARIN ? unclear Mechanistic
GLYBURIDE ? unclear Mechanistic
EPINEPHRINE ? unclear Mechanistic
SOMATROPIN (RECOMBINANT DNA ORIGIN) ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
PRASTERONE ? unclear Mechanistic
PD-98059 ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
NYSTATIN ? unclear Mechanistic
RESVERATROL ? unclear Mechanistic
LIOTHYRONINE ? unclear Mechanistic
SORBITOL ? unclear Mechanistic
IMATINIB ? unclear Mechanistic
SOYBEAN SEED OIL ? unclear Mechanistic
FLUORODEOXYGLUCOSE F18 ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
RETINOIC ACID AGENT ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
STREPTOZOCIN ? unclear Mechanistic
BETA-ADRENERGIC ANTAGONIST ? unclear Mechanistic
INDINAVIR ? unclear Mechanistic
OMAPATRILAT ? unclear Mechanistic
DEXAMETHASONE ? unclear Mechanistic
UCN-01 ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
GREEN TEA LEAF EXTRACT ? unclear Mechanistic
IRBESARTAN ? unclear Mechanistic
TNF-ALPHA ? unclear Mechanistic
ADENOVIRUS VECTOR ? unclear Mechanistic

Showing top 40 of 65 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TOFOGLIFLOZIN inhibits Mechanistic
SERGLIFLOZIN ETABONATE inhibits Mechanistic
IPRAGLIFLOZIN inhibits Mechanistic
LICOGLIFLOZIN inhibits Mechanistic
HENAGLIFLOZIN inhibits Mechanistic
YM-543 inhibits Mechanistic
GLUFOSFAMIDE ? unclear Mechanistic
DAPAGLIFLOZIN PROPANEDIOL inhibits Mechanistic
IPRAGLIFLOZIN L-PROLINE inhibits Mechanistic
REMOGLIFLOZIN ETABONATE inhibits Mechanistic
ERTUGLIFLOZIN PIDOLATE inhibits Mechanistic
EMPAGLIFLOZIN inhibits Mechanistic
ERTUGLIFLOZIN inhibits Mechanistic
SOTAGLIFLOZIN inhibits Mechanistic
CANAGLIFLOZIN inhibits Mechanistic
BEXAGLIFLOZIN inhibits Mechanistic
TOFOGLIFLOZIN ANHYDROUS ? unclear Mechanistic
DAPAGLIFLOZIN ? unclear Mechanistic 1.1 nM (EC50)
CHEMBL183937 inhibits Mechanistic 4.0 nM (Ki)
CHEMBL187805 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL187163 inhibits Mechanistic 9.0 nM (Ki)
CHEMBL187749 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL184530 inhibits Mechanistic 230.0 nM (Ki)
CHEMBL184027 inhibits Mechanistic 70.0 nM (Ki)
CHEMBL188013 inhibits Mechanistic 40.0 nM (Ki)
CHEMBL361672 inhibits Mechanistic 520.0 nM (Ki)
CHEMBL187056 inhibits Mechanistic 290.0 nM (Ki)
CHEMBL360824 inhibits Mechanistic 1280.0 nM (Ki)
CHEMBL184364 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL359962 inhibits Mechanistic 10.0 nM (Ki)
CHEMBL184183 inhibits Mechanistic 30.0 nM (Ki)
CHEMBL183790 inhibits Mechanistic 150.0 nM (Ki)
CHEMBL365222 inhibits Mechanistic 20.0 nM (Ki)
CHEMBL187686 inhibits Mechanistic 110.0 nM (Ki)
CHEMBL186823 inhibits Mechanistic 30.0 nM (Ki)
CHEMBL187060 inhibits Mechanistic 20.0 nM (Ki)
CHEMBL362365 inhibits Mechanistic 80.0 nM (Ki)
CHEMBL183689 inhibits Mechanistic 70.0 nM (Ki)
CHEMBL371448 inhibits Mechanistic 491.0 nM (IC50)
CHEMBL382302 inhibits Mechanistic 458.0 nM (IC50)

Showing top 40 of 190 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Type 2 Diabetes” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 45 not found by the gene-target search above.

Dapagliflozin

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00839683 NCT01042977 NCT03074630

Glimepiride

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00747383 NCT02769481 NCT00099944

metformin

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01941199 NCT02119819 NCT06120881

simvastatin

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00839683 NCT00839683

vildagliptin

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00237237 NCT00099944

Technosphere® Insulin Inhalation PowderNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00662857 NCT00662857

Semaglutide

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07564414 NCT00833716

valsartanNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00839683

Sitagliptin

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00747383

RosuvastatinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03074630

Liraglutide injection,RD12014NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05294536

Liraglutide injection,VictozaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05294536

Salba dietNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00362011

Tang-min-ling pills low dosageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01107171

Tang-min-ling pills high dosageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01107171

GSBR-1290NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05762471

HydrochlorothiazideNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00976495

Finerenone (Kerendia, BAY 948862)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05526157

Sodium-glucose cotransporter 2 inhibitors (SGLT2i)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05526157

Glucagon-like peptide-1 receptor agonists (GLP 1 RA)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05526157

Steroidal mineral corticoid receptor antagonists (sMRA)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05526157

Non-steroidal mineral corticoid receptor antagonists (nsMRA)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05526157

Bexagliflozin

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02769481

Placebo for BexagliflozinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02769481

Placebo for GlimepirideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02769481

PRECEDE HPE modelNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01316367

CHPENOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01316367

Bromocriptine-QRNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05405244

FinerenoneNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06727409

DA-1229NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01941199

DA-1229 + metforminNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01941199

Clenbuterol HydrochlorideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04921306

Non-ARB (standard therapy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01075698

ARB (Telmisartan)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01075698

blood donationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00230087

Pioglitazone

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00331487

Rosiglitazone

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00331487

RAA PopulationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00662857

Metformin glycinate

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01386671

Metformin hydrochloride

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01386671

Potato-based side dishNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03495284

Refined grain-basedNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03495284

LY3841136NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06603571

Tirzepatide

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06603571

LAF237 placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00099944

CagrisemaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07564414

LY2944876NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02119819

Exenatide extended-releaseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02119819

aleglitazar

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01871428

Black Impact InterventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06055036

Insulin glargine,300 U/mLNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02735044

Insulin glargine (100 units /mL)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02735044

Background therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02735044

Enhanced GI Concept EducationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03037099

Video-Based Diabetes Self-Management Education and Support (DSMES)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06319716

Community Health Worker (CHW) SupportNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06319716

Kerendia (Finerenone, BAY94-8862)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06906081

LY2189265NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01558271

Liraglutide

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01558271

AP-325NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05160272

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.